3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Uterine Cervical Neoplasms
2
Oropharyngeal Neoplasms
2
Hodgkin Disease
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Plasma Cell
1
Glioma
1
Disease
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
7
Nivolumab
6
enfortumab vedotin
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
4
sacituzumab govitecan
3
Gemcitabine
3
Docetaxel
3
CTLA-4 Antigen
3
cabozantinib
2
Taxes
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
temsirolimus
1
relatlimab
1
lenvatinib
1
eribulin
1
avelumab
1
atezolizumab
1
Valproic Acid
1
Sirolimus
1
Single Person
1
Radiosurgery
1
Platinum
1
Immunoglobulin G
1
Disulfides
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Fluorodeoxyglucose F18
×
30 days
×
Clear all
No trials found.